12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Niraparib: Phase III started

Tesaro began the double-blind, placebo-controlled, international Phase III NOVA trial to evaluate once-daily 300 mg niraparib in 28-day cycles in about 360 patients with high-grade serous, platinum-sensitive, relapsed ovarian cancer. The trial will enroll patients into 1 of 2 independent cohorts based on germline breast cancer early onset (BRCA) mutation...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >